At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 316 enrolled
Drug / intervention
ABT-450/r +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)
In Brief
A Phase 2 clinical trial evaluating ABT-450/r, ABT-267, and 1 other intervention for Hepatitis C, Chronic. Completed, enrolled 316 participants.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of co-administration of ABT-450 (also known as paritaprevir) with ritonavir (ABT-450/r) and ABT-267 (also known as ombitasvir) in adults with chronic hepatitis C virus infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2012
First PostedSep 2012
Primary CompletionJun 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedSep 14, 2012
Enrollment StartAug 1, 2012
Primary CompletionJun 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.8 years ago
Interventions
ABT-450/rdrug
Tablet; ABT-450; Capsule; ritonavir
ABT-267drug
Tablet
Ribavirin (RBV)drug
Tablet